Hemogenyx Pharmaceuticals plc is a preclinical-stage biotechnology company. The Company is focused on the discovery, development and commercialization of treatments relating to bone marrow/hematopoietic (blood-forming) stem cell (BM/HSC) transplants for blood diseases, including leukemia, lymphoma and bone marrow failure and viral infections.
It is developing several distinct and complementary product candidates, as well as a platform technology. To obviate the use of chemotherapeutic agents for conditioning of patients undergoing BM/HSC transplantations, the Company developed a method of selective elimination of hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in patients using highly specific CDX antibodies.
It has developed postnatal human hemogenic endothelial cells (Hu-PHEC cells) to generate cancer-free hematopoietic stem cells (HSC) for use in transplants to treat blood cancers. It has developed HEMO-CAR-T, for the potential treatment of acute myeloid leukemia (AML)..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 2.2M |
| Three Month Average Volume | 84.0M |
| High Low | |
| Fifty-Two Week High | 0.07134 GBX |
| Fifty-Two Week Low | 0.01164 GBX |
| Fifty-Two Week High Date | 09 Feb 2024 |
| Fifty-Two Week Low Date | 05 Aug 2024 |
| Price and Volume | |
| Current Price | 0.01309 GBX |
| Beta | 4 |
| Relative Price Change | |
| Four Week Relative Price Change | 0.37% |
| Thirteen Week Relative Price Change | -12.41% |
| Twenty-Six Week Relative Price Change | -38.44% |
| Fifty-Two Week Relative Price Change | -27.43% |
| Year-to-Date Relative Price Change | -47.37% |
| Price Change | |
| One Day Price Change | 1.39% |
| Thirteen Week Price Change | -11.25% |
| Twenty-Six Week Price Change | -32.87% |
| Five Day Price Change | 1.16% |
| Fifty-Two Week Price Change | -18.19% |
| Year-to-Date Price Change | -43.09% |
| Month-to-Date Price Change | 1.08% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.0024 GBX |
| Book Value Per Share (Most Recent Quarter) | 0.0024 GBX |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.002 GBX |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.002 GBX |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.00515 GBX |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 GBX |
| Revenue Per Share (Trailing Twelve Months) | 0 GBX |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 GBX |
| Dividend Per Share (Trailing Twelve Months) | 0 GBX |
| Dividend Per Share (5 Year) | -99999.99 GBX |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.00593 GBX |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.00609 GBX |
| Normalized (Last Fiscal Year) | -0.00593 GBX |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.00593 GBX |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.00609 GBX |
| Including Extraordinary Items (Last Fiscal Year) | -0.00593 GBX |
| Including Extraordinary Items (Trailing Twelve Months) | -0.00609 GBX |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.00106 GBX |
| Cash Per Share (Most Recent Quarter) | 0.00106 GBX |
| Cash Flow Per Share (Last Fiscal Year) | -0.00536 GBX |
| Cash Flow Per Share (Trailing Twelve Months) | -0.00536 GBX |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.00551 GBX |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -2.08% |
| Tangible Book Value (5 Year) | 27.89% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 36.68% |
| Total Debt (5 Year) | 20.23% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 32.99% |
| EPS Change (Trailing Twelve Months) | -50.00% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 7 |
| Price to Tangible Book (Most Recent Quarter) | 7 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 1.7M |
| Net Debt (Last Fiscal Year) | 1.7M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 5 |
| Price to Book (Most Recent Quarter) | 5 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 95 |
| Long Term Debt to Equity (Most Recent Quarter) | 95 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 3 |
| Current Ratio (Most Recent Quarter) | 3 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -6,222,860 |
| Free Cash Flow (Trailing Twelve Months) | -6,222,860 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -5 |
| Net Interest Coverage (Trailing Twelve Months) | -28 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 105 |
| Total Debt to Equity (Most Recent Quarter) | 105 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -101.47% |
| Return on Assets (Trailing Twelve Months) | -101.47% |
| Return on Assets (5 Year) | -82.19% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -219.58% |
| Return on Equity (Trailing Twelve Months) | -219.58% |
| Return on Equity (5 Year) | -138.86% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -112.85% |
| Return on Investment (Trailing Twelve Months) | -112.85% |
| Return on Investment (5 Year) | -95.97% |